Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9764MR)

This product GTTS-WQ9764MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3594MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ7938MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ3025MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ7936MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13634MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ282MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ2990MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ10708MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW